Drugs / GW824575
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01551771 Comparator | Feb → Apr 2012 | retinal disorder | GlaxoSmithKline | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GW824575 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01551771 ↗ |
| Action | Inhibit | “the CC-chemokine Receptor 3 (CCR3) Antagonist” NCT01551771 ↗ |
| Route | Oral | “GW824575, given as single and repeated oral doses” NCT01551771 ↗ |